Entrada Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

TRDA$5.25+11.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Collaboration revenue	$898	$1,950	$1,773	$22,508
Operating expenses:
Research and development	35,369	37,877	68,423	69,951
General and administrative	10,492	10,922	20,616	21,196
Total operating expenses	45,861	48,799	89,039	91,147
Loss from operations	(44,963)	(46,849)	(87,266)	(68,639)
Other income:
Interest and other income	2,235	3,924	4,859	8,365
Total other income	2,235	3,924	4,859	8,365
Loss before provision for income taxes	(42,728)	(42,925)	(82,407)	(60,274)
Provision for income taxes	35	178	73	178
Net loss	$(42,763)	$(43,103)	$(82,480)	$(60,452)
Net loss per share, basic and diluted	$(1.01)	$(1.04)	$(1.96)	$(1.47)
Weighted‑average common shares outstanding, basic and diluted	42,221,665	41,338,752	42,030,035	41,206,974
Other comprehensive (loss) gain
Unrealized (loss) gain on marketable securities	(180)	(37)	(586)	443
Total other comprehensive (loss) gain	(180)	(37)	(586)	443
Total comprehensive loss	$(42,943)	$(43,140)	$(83,066)	$(60,009)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.